Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $44.22

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has received an average recommendation of “Buy” from the ten analysts that are covering the company, MarketBeat reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in the last year is $44.22.

FDMT has been the subject of several research reports. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, March 1st. Royal Bank of Canada upped their price objective on 4D Molecular Therapeutics from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Barclays started coverage on 4D Molecular Therapeutics in a research note on Monday, April 15th. They issued an “overweight” rating on the stock. The Goldman Sachs Group restated a “buy” rating and set a $81.00 target price on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 7th. Finally, Jefferies Financial Group increased their price target on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a research report on Monday, April 1st.

Insiders Place Their Bets

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 6,244 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $27.50, for a total transaction of $171,710.00. Following the transaction, the insider now owns 1,737 shares in the company, valued at approximately $47,767.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Scott Bizily sold 6,244 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $27.50, for a total transaction of $171,710.00. Following the transaction, the insider now directly owns 1,737 shares of the company’s stock, valued at $47,767.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Robert Young Kim sold 24,552 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $30.05, for a total transaction of $737,787.60. Following the transaction, the insider now owns 1,043 shares in the company, valued at approximately $31,342.15. The disclosure for this sale can be found here. Insiders sold a total of 143,942 shares of company stock valued at $4,074,435 over the last ninety days. 7.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. boosted its holdings in shares of 4D Molecular Therapeutics by 35.6% during the 3rd quarter. RA Capital Management L.P. now owns 4,163,211 shares of the company’s stock worth $52,998,000 after buying an additional 1,093,680 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of 4D Molecular Therapeutics by 415.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 816,343 shares of the company’s stock worth $16,539,000 after purchasing an additional 658,069 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in 4D Molecular Therapeutics in the 1st quarter valued at approximately $13,718,000. Vontobel Holding Ltd. bought a new stake in 4D Molecular Therapeutics during the 4th quarter valued at $2,887,000. Finally, Sectoral Asset Management Inc. purchased a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth $2,887,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Price Performance

FDMT opened at $23.93 on Friday. 4D Molecular Therapeutics has a fifty-two week low of $9.44 and a fifty-two week high of $36.25. The company has a market capitalization of $1.22 billion, a P/E ratio of -9.00 and a beta of 2.87. The firm’s fifty day moving average price is $28.47 and its two-hundred day moving average price is $20.97.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.09). The firm had revenue of ($0.02) million during the quarter, compared to the consensus estimate of $4.67 million. 4D Molecular Therapeutics had a negative return on equity of 34.14% and a negative net margin of 436.30%. On average, equities research analysts expect that 4D Molecular Therapeutics will post -3.03 EPS for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.